Journal ArticleDOI
Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies
Alex J. Mitchell,Alex J. Mitchell,Melissa Chan,Henna Bhatti,Marie Halton,Luigi Grassi,Christoffer Johansen,Nicholas Meader +7 more
Reads0
Chats0
TLDR
Interview-defined depression and anxiety is less common in patients with cancer than previously thought, although some combination of mood disorders occurs in 30-40% of patients in hospital settings without a significant difference between palliative-care and non-palliatives-care settings.Abstract:
Summary Background Substantial uncertainty exists about prevalence of mood disorders in patients with cancer, including those in oncological, haematological, and palliative-care settings. We aimed to quantitatively summarise the prevalence of depression, anxiety, and adjustments disorders in these settings. Methods We searched Medline, PsycINFO, Embase, and Web of Knowledge for studies that examined well-defined depression, anxiety, and adjustment disorder in adults with cancer in oncological, haematological, and palliative-care settings. We restricted studies to those using psychiatric interviews. Studies were reviewed in accordance with PRISMA guidelines and a proportion meta-analysis was done. Findings We identified 24 studies with 4007 individuals across seven countries in palliative-care settings. Meta-analytical pooled prevalence of depression defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM) or International Classification of Diseases (ICD) criteria was 16·5% (95% CI 13·1–20·3), 14·3% (11·1–17·9) for DSM-defined major depression, and 9·6% (3·6–18·1) for DSM-defined minor depression. Prevalence of adjustment disorder alone was 15·4% (10·1–21·6) and of anxiety disorders 9·8% (6·8–13·2). Prevalence of all types of depression combined was of 24·6% (17·5–32·4), depression or adjustment disorder 24·7% (20·8–28·8), and all types of mood disorder 29·0% (10·1–52·9). We identified 70 studies with 10 071 individuals across 14 countries in oncological and haematological settings. Prevalence of depression by DSM or ICD criteria was 16·3% (13·4–19·5); for DSM-defined major depression it was 14·9% (12·2–17·7) and for DSM-defined minor depression 19·2% (9·1–31·9). Prevalence of adjustment disorder was 19·4% (14·5–24·8), anxiety 10·3% (5·1–17·0), and dysthymia 2·7% (1·7–4·0). Combination diagnoses were common; all types of depression occurred in 20·7% (12·9–29·8) of patients, depression or adjustment disorder in 31·6% (25·0–38·7), and any mood disorder in 38·2% (28·4–48·6). There were few consistent correlates of depression: there was no effect of age, sex, or clinical setting and inadequate data to examine cancer type and illness duration. Interpretation Interview-defined depression and anxiety is less common in patients with cancer than previously thought, although some combination of mood disorders occurs in 30–40% of patients in hospital settings without a significant difference between palliative-care and non-palliative-care settings. Clinicians should remain vigilant for mood complications, not just depression. Funding None.read more
Citations
More filters
Journal ArticleDOI
Cancer treatment and survivorship statistics, 2012
Rebecca L. Siegel,Carol DeSantis,Katherine S. Virgo,Kevin Stein,Angela B. Mariotto,Tenbroeck Smith,Dexter L. Cooper,Ted Gansler,Catherine C. Lerro,Stacey A. Fedewa,Chun Chieh Lin,Corinne R. Leach,Rachel S. Cannady,Hyunsoon Cho,Steve Scoppa,Mark Hachey,Rebecca A. Kirch,Ahmedin Jemal,Elizabeth Ward +18 more
TL;DR: Common cancer treatments, survival rates, and posttreatment concerns are summarized and the new National Cancer Survivorship Resource Center is introduced, which has engaged more than 100 volunteer survivorship experts nationwide to develop tools for cancer survivors, caregivers, health care professionals, advocates, and policy makers.
Journal ArticleDOI
Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism
Peng Zheng,B Zeng,Chanjuan Zhou,M Liu,Z Fang,X Xu,L Zeng,Jianjun Chen,S Fan,X Du,X Zhang,D Yang,Y Yang,H Meng,Wei-Wei Li,Narayan D. Melgiri,Julio Licinio,H Wei,Peng Xie +18 more
TL;DR: It is demonstrated that dysbiosis of the gut microbiome may have a causal role in the development of depressive-like behaviors, in a pathway that is mediated through the host’s metabolism.
Journal ArticleDOI
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
Roland R. Griffiths,Matthew W. Johnson,Michael A. Carducci,Annie Umbricht,William A. Richards,Brian D Richards,Mary P Cosimano,Margaret A. Klinedinst +7 more
TL;DR: High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety.
Journal ArticleDOI
Anxiety and depression after cancer diagnosis: Prevalence rates by cancer type, gender, and age
TL;DR: Given that levels of anxiety and depression varied widely by cancer type, gender, and age, these results inform which cancer patients are most likely in need of psychosocial support.
Journal ArticleDOI
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Stephen Ross,Anthony P. Bossis,Jeffrey Guss,Gabrielle Agin-Liebes,Tara C. Malone,Barry H. Cohen,Sarah E. Mennenga,Alexander B. Belser,Krystallia Kalliontzi,James Babb,Zhe Su,Patricia Corby,Brian L. Schmidt +12 more
TL;DR: Psilocybin was associated with enduring anxiolytic and anti-depressant effects in patients with cancer-related psychological distress, sustained benefits in existential distress and quality of life, as well as improved attitudes towards death.
References
More filters
Journal ArticleDOI
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
TL;DR: Moher et al. as mentioned in this paper introduce PRISMA, an update of the QUOROM guidelines for reporting systematic reviews and meta-analyses, which is used in this paper.
Journal Article
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
TL;DR: The QUOROM Statement (QUality Of Reporting Of Meta-analyses) as mentioned in this paper was developed to address the suboptimal reporting of systematic reviews and meta-analysis of randomized controlled trials.
Journal ArticleDOI
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
TL;DR: A structured summary is provided including, as applicable, background, objectives, data sources, study eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings.